Topic List : Cancer
Iron nanoparticles help treat cancer
Stanford researchers accidentally discovered that iron nanoparticles invented for anemia treatment have another use: triggering the immune system’s ability to destroy tumor cells.
Pediatric cancer grants announced
Kara Davis, Melissa Mavers and Liora Schultz awarded St. Baldrick’s Foundation grants.
Study on treatment decisions seeks participants
The study is designed to collect neurophysiological and psychological information from women faced with a breast cancer diagnosis and many treatment decisions.
Retinoic acid deficiency linked to tumors
Levels of retinoic acid, a vitamin A metabolite, are low in mice and humans with colorectal cancer, according to new research. People with high levels of an enzyme that degrades retinoic acid have a poor prognosis.
Extra chemo ineffectual against rare bone cancer
Osteosarcoma patients with tumors that haven’t responded well to the standard chemotherapy regimen have unimproved outcomes and more side effects when given two additional drugs, a large international trial has found.
Cancer’s new paradigm
Cancer cells can be as cooperative as a flock of birds, making individual decisions yet somehow acting in unison. A Stanford researcher is using this insight to make a computer model of cancer.
Computers trained in pathology
Automating the analysis of slides of lung cancer tissue samples increases the accuracy of tumor classification and patient prognoses, according to a new study.
A safer way for bone marrow transplants
Scientists have devised a way to destroy blood stem cells in mice without using chemotherapy or radiotherapy, both of which have toxic side effects.
Cancer institute earns comprehensive status
The designation is recognition of the Stanford Cancer Institute’s robust and integrated programs encompassing laboratory research, clinical care and community outreach and education.
Treating rare blood cancers
Patients with a group of cancers known as advanced systemic mastocytosis have few treatment options. A drug called midostaurin showed promise in an international clinical trial led by a Stanford physician.